1849636-24-3

1849636-24-3 structure

Name: Tibulizumab
Chemical Name: Tibulizumab
CAS Number: 1849636-24-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-04-11 10:38:40
Modify Date: 2024-01-20 18:07:37
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1].

Name	Tibulizumab

Description	Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-17A:14 pM (Kd) BAFF:60 pM (Kd)
In Vitro	Tibulizumab (LY 3090106) 与小鼠 BAFF 结合，KD 为 340 nM，但不与小鼠 IL-17 结合。Tibulizumab 与猕猴 BAFF 和猕猴 IL-17 结合，KD 分别为 26.8 pM 和 19 pM[1]。在 HT-29 细胞中，Tibulizumab 以浓度依赖性方式拮抗 IL-17 诱导的 CXCL1 分泌 (IC50 为 2.00 nM)。在 T1165 细胞中，Tibulizumab 以浓度依赖性方式阻断 BAFF 诱导的增殖 (IC50 为 0.064 nM)。Tibulizumab 同时结合并阻断 BAFF 和 IL-17[1]。
In Vivo	Tibulizumab（LY 3090106；660 µg/小鼠，i.p；66 µg/小鼠，s.c）在小鼠体内有效拮抗人 BAFF 和 IL-17 诱导的生物学效应[1]。在食蟹猴中，Tibulizumab（i.v，0.3、1、5 或 20 mg/kg；或 s.c，5 mg/kg）抑制 B 细胞发育和存活，并在循环中保持功能完整，并延长半衰期 [1]。
References	[1]. Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11(6):1175-1190.

No Any Chemical & Physical Properties